wannabe
09-14-2006, 01:24 PM
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-14-2006/0004432833&EDATE=
Although trial on hold due to effect on immune system.
Analysis of the first co-primary endpoint showed that patients taking
alemtuzumab at high and low doses experienced at least a 75 percent
reduction in the risk for relapse after at least two years of follow up
when compared to patients treated with interferon beta-1a. This difference
was statistically significant in favor of the alemtuzumab patients at both
high and low doses, with a p-value less than the pre-specified value
(p=0.00328) assigned for the two-year interim analysis.
Analysis of the other co-primary endpoint showed that patients taking
alemtuzumab at high and low doses experienced at least a 65 percent
reduction in the risk for progression of clinically significant disability
when compared to patients treated with interferon beta-1a. This difference
was statistically significant in favor of the alemtuzumab patients at both
high and low doses, with a p-value less than the pre-specified value
(p=0.01194) assigned for the two-year interim analysis.
Although trial on hold due to effect on immune system.
Analysis of the first co-primary endpoint showed that patients taking
alemtuzumab at high and low doses experienced at least a 75 percent
reduction in the risk for relapse after at least two years of follow up
when compared to patients treated with interferon beta-1a. This difference
was statistically significant in favor of the alemtuzumab patients at both
high and low doses, with a p-value less than the pre-specified value
(p=0.00328) assigned for the two-year interim analysis.
Analysis of the other co-primary endpoint showed that patients taking
alemtuzumab at high and low doses experienced at least a 65 percent
reduction in the risk for progression of clinically significant disability
when compared to patients treated with interferon beta-1a. This difference
was statistically significant in favor of the alemtuzumab patients at both
high and low doses, with a p-value less than the pre-specified value
(p=0.01194) assigned for the two-year interim analysis.